These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37598924)

  • 1. Regorafenib activates oxidative stress by inhibiting SELENOS and potentiates oxaliplatin-induced cell death in colon cancer cells.
    Yu Y; Wu T; Zhang X; Li P; Ye L; Kuang J; Tao L; Ni L; Zhao Q; Zhang J; Pan H; Xie C; Zheng C; Li S; Cui R
    Eur J Pharmacol; 2023 Oct; 957():175986. PubMed ID: 37598924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regorafenib induces NOX5-mediated endoplasmic reticulum stress and potentiates the anti-tumor activity of cisplatin in non-small cell lung cancer cells.
    Sui H; Xiao S; Jiang S; Wu S; Lin H; Cheng L; Ye L; Zhao Q; Yu Y; Tao L; Kong FM; Huang X; Cui R
    Neoplasia; 2023 May; 39():100897. PubMed ID: 36940556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dihydroartemisinin enhances the anti-tumor activity of oxaliplatin in colorectal cancer cells by altering PRDX2-reactive oxygen species-mediated multiple signaling pathways.
    Yu Y; Chen D; Wu T; Lin H; Ni L; Sui H; Xiao S; Wang C; Jiang S; Pan H; Li S; Jin X; Xie C; Cui R
    Phytomedicine; 2022 Apr; 98():153932. PubMed ID: 35104762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Shikonin potentiates therapeutic efficacy of oxaliplatin through reactive oxygen species-mediated intrinsic apoptosis and endoplasmic reticulum stress in oxaliplatin-resistant colorectal cancer cells.
    Zhang Z; Shen C; Zhou F; Zhang Y
    Drug Dev Res; 2023 May; 84(3):542-555. PubMed ID: 36779379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Echinatin induces reactive oxygen species-mediated apoptosis via JNK/p38 MAPK signaling pathway in colorectal cancer cells.
    Kwak AW; Lee JY; Lee SO; Seo JH; Park JW; Choi YH; Cho SS; Yoon G; Lee MH; Shim JH
    Phytother Res; 2023 Feb; 37(2):563-577. PubMed ID: 36184899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer.
    Schmieder R; Hoffmann J; Becker M; Bhargava A; Müller T; Kahmann N; Ellinghaus P; Adams R; Rosenthal A; Thierauch KH; Scholz A; Wilhelm SM; Zopf D
    Int J Cancer; 2014 Sep; 135(6):1487-96. PubMed ID: 24347491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolinderalactone sensitizes oxaliplatin-resistance colorectal cancer cells through JNK/p38 MAPK signaling pathways.
    Kwak AW; Park JW; Lee SO; Lee JY; Seo JH; Yoon G; Lee MH; Choi JS; Shim JH
    Phytomedicine; 2022 Oct; 105():154383. PubMed ID: 35987016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress.
    Kopetz S; Lesslie DP; Dallas NA; Park SI; Johnson M; Parikh NU; Kim MP; Abbruzzese JL; Ellis LM; Chandra J; Gallick GE
    Cancer Res; 2009 May; 69(9):3842-9. PubMed ID: 19383922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The synergistic effects of oxaliplatin and piperlongumine on colorectal cancer are mediated by oxidative stress.
    Chen W; Lian W; Yuan Y; Li M
    Cell Death Dis; 2019 Aug; 10(8):600. PubMed ID: 31395855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Piperlongumine potentiates the antitumor efficacy of oxaliplatin through ROS induction in gastric cancer cells.
    Zhang P; Shi L; Zhang T; Hong L; He W; Cao P; Shen X; Zheng P; Xia Y; Zou P
    Cell Oncol (Dordr); 2019 Dec; 42(6):847-860. PubMed ID: 31493144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ethaselen synergizes with oxaliplatin in tumor growth inhibition by inducing ROS production and inhibiting TrxR1 activity in gastric cancer.
    Zhang H; Wu J; Yuan J; Li H; Zhang Y; Wu W; Chen W; Wang C; Meng S; Chen S; Huo M; He Y; Zhang C
    J Exp Clin Cancer Res; 2021 Aug; 40(1):260. PubMed ID: 34412665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of oxaliplatin-induced colon cancer cell apoptosis by alantolactone, a natural product inducer of ROS.
    Cao P; Xia Y; He W; Zhang T; Hong L; Zheng P; Shen X; Liang G; Cui R; Zou P
    Int J Biol Sci; 2019; 15(8):1676-1684. PubMed ID: 31360110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of PGE
    Huang H; Aladelokun O; Ideta T; Giardina C; Ellis LM; Rosenberg DW
    Sci Rep; 2019 Mar; 9(1):4954. PubMed ID: 30894570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CPT2 downregulation triggers stemness and oxaliplatin resistance in colorectal cancer via activating the ROS/Wnt/β-catenin-induced glycolytic metabolism.
    Li H; Chen J; Liu J; Lai Y; Huang S; Zheng L; Fan N
    Exp Cell Res; 2021 Dec; 409(1):112892. PubMed ID: 34688609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regorafenib suppresses colon tumorigenesis and the generation of drug resistant cancer stem-like cells via modulation of miR-34a associated signaling.
    Cai MH; Xu XG; Yan SL; Sun Z; Ying Y; Wang BK; Tu YX
    J Exp Clin Cancer Res; 2018 Jul; 37(1):151. PubMed ID: 30005681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intense endoplasmic reticulum stress (ERS) / IRE1α enhanced Oxaliplatin efficacy by decreased ABCC10 in colorectal cancer cells.
    Liu X; Wu B; Chen H; Sun H; Guo X; Sun T; Zhou D; Yang S
    BMC Cancer; 2022 Dec; 22(1):1369. PubMed ID: 36585626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term survival of a patient with microsatellite-stable refractory colorectal cancer with regorafenib and PD-1 inhibitor sintilimab: a case report and review of literature.
    Zhang Y; Zhang F; Zhao L; Fu X; Shang Y; Gao Q
    BMC Gastroenterol; 2021 Oct; 21(1):399. PubMed ID: 34688262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Class I HDAC Inhibitor, MS-275, Prevents Oxaliplatin-Induced Chronic Neuropathy and Potentiates Its Antiproliferative Activity in Mice.
    Lamoine S; Cumenal M; Barriere DA; Pereira V; Fereyrolles M; Prival L; Barbier J; Boudieu L; Brasset E; Bertin B; Renaud Y; Miot-Noirault E; Civiale MA; Balayssac D; Aissouni Y; Eschalier A; Busserolles J
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of Bcl-xL in synergistic induction of apoptosis by mapatumumab and oxaliplatin in combination with hyperthermia on human colon cancer.
    Song X; Kim SY; Lee YJ
    Mol Cancer Res; 2012 Dec; 10(12):1567-79. PubMed ID: 23051936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. WBSCR22 confers oxaliplatin resistance in human colorectal cancer.
    Yan D; Tu L; Yuan H; Fang J; Cheng L; Zheng X; Wang X
    Sci Rep; 2017 Nov; 7(1):15443. PubMed ID: 29133897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.